Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!

Even Exact Sciences Bulls Wonder If Expectations Are Lofty

Courtesy of Benzinga.

Even Exact Sciences Bulls Wonder If Expectations Are Lofty

EXACT Sciences Corporation (NASDAQ: EXAS) shares have been on a heady run this year. Despite the sell side’s optimism on the company’s fundamentals, analysts have become wary of Exact’s astronomical valuation, with the company holding its highest valuation since the summer of 2015.

The Analyst & Rating

Baird analyst Catherine Ramsey Schulte downgraded shares of Exact Sciences from Outperform to Neutral, with a price target of $56.

The Thesis

Exact Sciences has continued to report impressive quarters and steadily improving utilization, Ramsey Schulte said in a Monday note. Cologuard’s positioning in quality measures and insurance coverage is strong, the analyst said. (See Ramsey Schulte’s track record here.)

Expectations going into 2018 are high, according to Baird. Using a $450 average selling price, or ASP, estimate for 2018, the Street estimate for Exact sits at 930,000 completed tests versus Baird’s estimate of 874,797.

The gap could be magnified further when guiding for the full year, Ramsey Schulte said.

Exact is in the habit of guiding conservatively and then beating its guidance, the analyst said. The company’s guidance range for the fourth quarter suggests that it might be attempting to rein in expectations a bit, the Ramsey Schulte said.

“With a $7 billion-plus market cap, it certainly feels like big numbers are expected,” she said. 

“We continue to have a very positive outlook on the business, but believe it’s worth staying on the sidelines until expectations for 2018 have been set.”

The Price Action

At the time of writing, shares of Exact Sciences were shedding 3.45 percent to $58.29.

The stock is up a staggering 336 percent year-to-date. 

Related Links: 

Risk-Reward Still Suggests Exact Sciences Is A Buy, But Be Cautious

Attention Biotech Investors: Here Are November PDUFA Catalysts On The Horizon

Photo courtesy of Exact Sciences. 

Latest Ratings for EXAS

Date Firm Action From To
Nov 2017 Leerink Swann Maintains Outperform
Nov 2017 Baird Downgrades Outperform Neutral
Nov 2017 BTIG Research Downgrades Buy Neutral

View More Analyst Ratings for EXAS


View the Latest Analyst Ratings

Posted-In: Baird Catherine Ramsey SchulteAnalyst Color Downgrades Analyst Ratings Best of Benzinga


Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!





You must be logged in to make a comment.
You can sign up for a membership or get a FREE Daily News membership or log in

Sign up today for an exclusive discount along with our 30-day GUARANTEE — Love us or leave, with your money back! Click here to become a part of our growing community and learn how to stop gambling with your investments. We will teach you to BE THE HOUSE — Not the Gambler!

Click here to see some testimonials from our members!